LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

Search

Novo Nordisk A-S

Suletud

SektorTervishoid

55.6 -0.82

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

55.36

Max

55.62

Põhinäitajad

By Trading Economics

Sissetulek

-2.5B

27B

Müük

-1.2B

77B

P/E

Sektori keskmine

15.409

35.69

Aktsiakasum

6.53

Dividenditootlus

2.84

Kasumimarginaal

34.484

Töötajad

78,387

EBITDA

-2.5B

44B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+7.79% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.84%

3.08%

Turustatistika

By TradingEconomics

Turukapital

52B

268B

Eelmine avamishind

56.42

Eelmine sulgemishind

55.6

Uudiste sentiment

By Acuity

74%

26%

341 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Novo Nordisk A-S Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. aug 2025, 13:52 UTC

Suurimad hinnamuutused turgudel

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

18. aug 2025, 09:23 UTC

Suurimad hinnamuutused turgudel

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

18. aug 2025, 09:23 UTC

Suurimad hinnamuutused turgudel

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

6. aug 2025, 06:52 UTC

Tulu

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6. aug 2025, 06:21 UTC

Tulu

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

22. sept 2025, 13:43 UTC

Omandamised, ülevõtmised, äriostud

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

18. sept 2025, 12:30 UTC

Market Talk

Correction to Novo Nordisk Market Talk

18. sept 2025, 12:00 UTC

Market Talk

Novo Nordisk's Prospects Could Turn Around -- Market Talk

18. sept 2025, 08:55 UTC

Kuumad aktsiad

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

11. sept 2025, 10:59 UTC

Market Talk

Novo Nordisk Investors Cheer Plans to Slim Organization -- Market Talk

10. sept 2025, 13:24 UTC

Tulu

Ozempic Maker Novo Nordisk to Cut 9,000 Jobs -- Update

10. sept 2025, 09:16 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Oracle, GameStop, Novo Nordisk -- WSJ

2. sept 2025, 09:14 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Nestlé, Novo Nordisk, Nvidia -- WSJ

21. aug 2025, 08:49 UTC

Tulu
Kuumad aktsiad

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

18. aug 2025, 09:23 UTC

Kuumad aktsiad

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

8. aug 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7. aug 2025, 11:32 UTC

Tulu

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7. aug 2025, 11:03 UTC

Tulu

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7. aug 2025, 10:41 UTC

Tulu

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6. aug 2025, 20:34 UTC

Tulu

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6. aug 2025, 08:45 UTC

Tulu

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6. aug 2025, 07:19 UTC

Market Talk
Tulu

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6. aug 2025, 05:50 UTC

Tulu

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6. aug 2025, 05:48 UTC

Tulu

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6. aug 2025, 05:46 UTC

Tulu

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6. aug 2025, 05:38 UTC

Tulu

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6. aug 2025, 05:37 UTC

Tulu

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

6. aug 2025, 05:36 UTC

Tulu

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

6. aug 2025, 05:35 UTC

Tulu

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

6. aug 2025, 05:34 UTC

Tulu

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

Võrdlus sarnastega

Hinnamuutus

Novo Nordisk A-S Prognoos

Hinnasiht

By TipRanks

7.79% tõus

12 kuu keskmine prognoos

Keskmine 59.94 USD  7.79%

Kõrge 70 USD

Madal 50 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Novo Nordisk A-S 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

5

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

62.63 / 69.23Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

341 / 371 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat